| 翻訳と辞書 |
Ramucirumab
Ramucirumab〔(Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab ), ''American Medical Association''.〕 (IMC-1121B, trade name Cyramza〔(FierceBiotech: FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer )〕〔(Cyramza official website )〕) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.〔(Ramucirumab (Cyramza) package insert )〕 This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
==Approved uses==
On April 21, 2014, the FDA approved ramucirumab, as a single agent or with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma if the disease has progressed despite fluoropyrimidine- or platinum-containing chemotherapy.〔(FDA.gov press release for ramucirumab approval, accessed April 22, 2014 )〕〔(Ramucirumab gastric cancer regimen & reference )〕
On December 12, 2014, the FDA approved ramucirumab in combination with docetaxel, for treatment of metastatic non-small-cell lung carcinoma with disease progression on or after platinum-containing chemotherapy. If the cancer has a sensitizing mutation of EGFR or ALK previous therapy should have included targeted therapy for the genomic tumor aberration.〔()〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Ramucirumab」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|